<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761185</url>
  </required_header>
  <id_info>
    <org_study_id>HIPEC-RAL</org_study_id>
    <nct_id>NCT04761185</nct_id>
  </id_info>
  <brief_title>Raltitrexed in HIPEC</brief_title>
  <official_title>Phase I Clinical Human Tolerability Test of Raltitrexed in Hyperthermic Intraperitoneal Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the tolerance of patients with colorectal cancer to hyperthermic intraperitoneal&#xD;
      chemotherapy with Raltitrexed, to determine the dose limiting toxicity and maximum tolerated&#xD;
      dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicity dose</measure>
    <time_frame>1 year</time_frame>
    <description>to determine dose-limiting toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tolerable dose</measure>
    <time_frame>1 year</time_frame>
    <description>to determine maximum tolerable dose</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Raltitrexed</condition>
  <condition>HIPEC</condition>
  <arm_group>
    <arm_group_label>HIPEC using Raltitrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltitrexed</intervention_name>
    <description>Raltitrexed in HIPEC</description>
    <arm_group_label>HIPEC using Raltitrexed</arm_group_label>
    <other_name>HIPEC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 18-75 (including 18 and 75), regardless of gender;&#xD;
&#xD;
          2. ECOG score ≤1;&#xD;
&#xD;
          3. Patients with colorectal adenocarcinoma/mucinous adenocarcinoma/signet ring cell&#xD;
             carcinoma/mucinous tumor confirmed by histopathology;&#xD;
&#xD;
          4. The laboratory test results within 1 week before treatment meet the following&#xD;
             conditions:&#xD;
&#xD;
             White blood cell (WBC) ≥ 4.0×109 /L;Neutrophil count (ANC) ≥ 1.8×109 /L;Platelet (PLT)&#xD;
             ≥ 100×109/L;Hemoglobin (Hb) ≥ 80 g/L;Serum total bilirubin (TB) ≤ 1.5×ULN;Serum&#xD;
             aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT)≤&#xD;
             2.5×ULN;Blood urea nitrogen (BUN) and blood creatinine (Cr) ≤ 1.5×ULN;&#xD;
&#xD;
          5. Patients voluntarily participate in this study, sign written informed consent, have&#xD;
             good compliance and are willing to cooperate with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe complications were considered to be intolerant of postoperative&#xD;
             chemotherapy;&#xD;
&#xD;
          2. Previous or concurrent malignancy, excluding cured carcinoma in situ of the cervix,&#xD;
             basal cell carcinoma of the skin or squamous cell carcinoma of the skin;&#xD;
&#xD;
          3. Patients with peptic ulcer, gastrointestinal dynamic obstruction, severe active&#xD;
             bleeding of the digestive tract, and perforation of the digestive tract;&#xD;
&#xD;
          4. Those with a history of allergy to the drug components or metabolites in the program;&#xD;
&#xD;
          5. A history of immunodeficiency, including HIV positive, other acquired or congenital&#xD;
             immunodeficiency diseases, or a history of organ transplantation;&#xD;
&#xD;
          6. had any heart disease, including :(1) angina;(2) Arrhythmia requiring medical&#xD;
             treatment or clinically significant;(3) Myocardial infarction;(4) Heart failure;(5)&#xD;
             any other heart disease deemed unfit to participate in this study by the researcher;&#xD;
&#xD;
          7. Female patients during pregnancy and lactation, female patients with fertility and&#xD;
             positive test of baseline pregnancy or female patients of childbearing age who are&#xD;
             unwilling to take effective contraceptive measures during the whole test period;&#xD;
&#xD;
          8. The accompanying diseases (including but not limited to hypertension, severe diabetes,&#xD;
             active infection, thyroid disease, etc.) that, according to the judgment of the&#xD;
             researcher, seriously endanger the safety of the patient or affect the completion of&#xD;
             the study;&#xD;
&#xD;
          9. A past history of neurological or mental disorders, such as major depression,&#xD;
             epilepsy, or dementia, that clearly affect study disclosure or follow-up evaluation;&#xD;
&#xD;
         10. Participate in other clinical trials within 30 days of enrollment and receive research&#xD;
             drugs and any concomitant treatment containing research drugs;&#xD;
&#xD;
         11. Other conditions in which the investigator considers it inappropriate to participate&#xD;
             in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guoxiang Cai, MD</last_name>
    <phone>+8664175590</phone>
    <email>gxcai@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoxiang Cai, MD</last_name>
      <email>gxcai@fudan.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Guoxiang Cai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renjie Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Raltitrexed</keyword>
  <keyword>HIPEC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

